1672.HK

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$10M	+821.4%	$-0.52	$-0.60–$-0.44	—	2
2027	$47M	+368.2%	$-0.64	$-1.02–$-0.44	—	3
2028	$750M	+1508.4%	$-0.03	$-0.36–$0.14	—	3

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-31	$-0.23	$-0.35	-53.7%
2026-03-31	$-0.31	$-0.31	+0.0%
2025-08-15	$-0.14	$-0.10	+29.7%
2025-03-26	$-0.16	$-0.18	-13.3%
2024-08-30	$-0.13	$-0.14	-6.8%
2024-03-25	$-0.07	$-0.13	-88.6%
2023-08-20	$-0.02	$-0.02	+24.0%
2023-03-19	$-0.17	$-0.52	-206.7%

DCF fair valuemodel estimate

Intrinsic value

$1.73

Price

$8.68

Implied downside

-80%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
1672.HKAscletis Pharma Inc.	$8.94	-0.67%	$9.4B	—
0775.HKCK Life Sciences International (Holdings), Inc.	$0.54	-1.82%	$5.2B	—
1477.HKOcumension Therapeutics	$5.34	-0.84%	$4.3B	—
2142.HKHBM Holdings Limited	$12.73	-4.86%	$10.7B	—
2157.HKLepu Biopharma Co., Ltd.	$3.98

Ascletis Pharma Inc.

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.

www.ascletis.com

Employees: 202
IPO / List date: Aug 1, 2018
HQ: HK

Held by traders on TradeandTell

No one on the platform currently holds 1672.HK.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 1672.HK as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 1672.HK yet.